What is Nurix Therapeutics, Inc.'s stock issuance proceeds?

Nurix Therapeutics, Inc. (NRIX) reported stock issuance proceeds of $18M in Q4 2025.

What is the long-term trend for Nurix Therapeutics, Inc.'s stock issuance proceeds?

Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $19.4M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Nurix Therapeutics, Inc. NRIX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Kymera TherapeuticsKYMR

$19.19M—

Monte Rosa Therapeutics, Inc.GLUE

$4.52M+32,200%

Stoke Therapeutics, Inc.STOK

$3.21M+219%

Viridian Therapeutics, Inc.VRDN

$0-100%

Nuvation BioNUVB

$908K-16.1%

Celldex TherapeuticsCLDX

$327K+61.9%

Other financials

Income statement

See full

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Balance sheet

See full

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Cash flow

See full

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Valuation

See full

Market cap$1.95B+40.1%

Enterprise value$1.94B+45.1%

P/S27.2×+2.5×

Profitability

See full

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Returns & leverage

See full

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s stock issuance proceeds?: Nurix Therapeutics, Inc. (NRIX) reported stock issuance proceeds of $18M in Q4 2025.
What is the long-term trend for Nurix Therapeutics, Inc.'s stock issuance proceeds?: Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $19.4M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.